At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
The move will add new global talent to Cytel’s Strategic Consulting group
Construction is now underway with the facility scheduled to be operational by 2025
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Subscribe To Our Newsletter & Stay Updated
